mechnikov institute, s.a.
OUR PRODUCTS
Flu-M
VAIF
В планах
Flu-М
FLU-M® [VACUNA ANTIGRIPAL(VIRUS FRACCIONADOS, INACTIVADOS)]
Flu-M® [influenza vaccine (split viruses, inactivated)] combines 7 antigens (surface and internal) of influenza virus subtype A (H1N1), subtype A (H3N2) and type B. High purity vaccine in phosphate buffered saline ...
The main characteristics of the ingredients of the Flu-M vaccine and an indicator of quality are their ability to develop an effective immune response against strains circulating in the world and of great epidemiological importance.
In the technological production process, optimal production conditions are adapted for:

  • Maintaining stable antigen-protective properties necessary to ensure effective antigen-cell interaction, and maintaining the so-called "confirmatory protective epitope".
  • Manufacturing of pharmaceutical products that meet all international requirements.

The protein hemagglutinin is a key protective antigen. Hemagglutinin is an integral membrane protein with a tendency to aggregation. Flu-M contains a stabilizer that prevents hemagglutinin aggregation and loss of its antigenic qualities.
Highly purified antigens of low reactogenicity are used to obtain FLU-M®.

The vaccine has a relatively low level of side effects, its characteristics of immunobiological activity comply with international requirements for influenza vaccines and guarantee immunity against influenza after its administration.
Final composition of FLU-M®
[VACUNA ANTIGRIPAL(VIRUS FRACCIONADOS, INACTIVADOS)]
Active ingredients
Auxiliary substances:
VAIF
VAIF (VACUNA ANTIGRIPAL INACTIVADA FRACCIONADA)

VAIF (Fractionated Inactivated Influenza Vaccine) combines 6 antigens (surface and internal) of influenza virus subtype A (H1N1), subtype A (H3N2) and type B. A highly purified vaccine in phosphate buffered saline.

The main characteristics of VAIF ingredients and the quality indicator is their ability to develop an effective immune response against strains of great epidemiological importance circulated in the world.
During the technological production process, the optimal manufacturing conditions have been adapted to:

  1. Maintain stable antigen protective qualities necessary to ensure effective antigen-cell interaction and preserve the so-called “confirmatory protective epitopes”.
  2. Manufacture a pharmaceutical product that meets all international requirements.

Hemagglutinin protein is a key protective antigen. Hemagglutinin is an integral membrane protein with a tendency to aggregation.

Highly purified low reactogenicity antigens are used to make VAIF. The vaccine has a relatively low level of adverse effects, its characteristics of immunobiological activity comply with international requirements for influenza vaccines and guarantee immunity against influenza after its application.
Final composition of the VAIF
(Fractionated inactivated influenza vaccine)
Active ingredients
Auxiliary substances:
Check back later